{
    "pmid": "41438748",
    "title": "Enhanced efficacy of lung cancer treatment with radiotherapy and immune checkpoint inhibitors without increased pneumonia risk: a systematic review and meta-analysis of randomized controlled trials.",
    "abstract": "Combined modality treatment with chemotherapy, radiotherapy, and immunotherapy is a crucial therapeutic approach for lung cancer. However, controversies still exist regarding radiation doses, treatment regimens, and the risk of pneumonitis. This study aimed to conduct a comprehensive meta-analysis and in-depth subgroup analyses based on randomized controlled trials (RCTs) involving lung cancer patients undergoing radiotherapy to assess whether its combination with immunotherapy is effective and safe. We systematically searched PubMed, Cochrane Central, Embase, and major conferences for randomized trials evaluating immune checkpoint inhibitors (ICIs) plus radiotherapy in lung cancer. The outcomes included progression-free survival (PFS), overall survival (OS), and the incidence of adverse reactions, particularly focusing on pneumonitis/pneumonia. Subgroup analyses were performed based on radiotherapy modalities, the timing of ICIs treatment, tumor stage, pathological type, and types of ICIs. Fifteen trials were included in this analysis. The addition of ICIs to radiotherapy or chemoradiotherapy significantly improved PFS (HR = 0.76, 95% CI 0.70-0.83) and OS (HR = 0.83, 95% CI 0.75-0.92). In subgroup analyses, stereotactic body radiotherapy (SBRT) (HR = 0.38, 95% CI 0.19-0.75) and hypo-fractionated radiotherapy (Hypo-RT) (HR = 0.49, 95% CI 0.31-0.79) were associated with improved PFS. Consolidation ICIs treatment improved OS (HR = 0.68, 95% CI 0.59-0.79), while concurrent ICIs had no significant effect (HR = 1.06, 95% CI 0.87-1.28). In terms of tumor stage, Stage I NSCLC patients (HR = 0.38, 95% CI 0.19-0.75) showed significant PFS improvement with ICIs. Both PD-1 (HR = 0.39, 95% CI 0.22-0.69) and PD-L1 (HR = 0.75, 95% CI 0.64-0.87) inhibitors were linked to improved PFS in irradiated lung cancer patients, and PD-L1 also enhanced OS (HR = 0.82, 95% CI 0.68-0.99). The addition of ICIs increased the risk of any-grade pneumonitis/pneumonia (RR = 1.27, 95% CI 1.12-1.44) but did not elevate the risk of severe (grade â‰¥3) events (RR = 1.12, 95% CI 0.78-1.60). Notably, among patients treated with SBRT, no significant increase was observed in the incidence of pneumonitis of any grade. PD-1/PD-L1 inhibitors combined with radiotherapy especially SBRT can enhance survival outcomes in lung cancer without increasing the risk of severe pneumonitis/pneumonia, supporting their clinically manageable safety profile. https://www.crd.york.ac.uk/PROSPERO/home, identifier CRD420251140111.",
    "disease": "pneumonia",
    "clean_text": "enhanced efficacy of lung cancer treatment with radiotherapy and immune checkpoint inhibitors without increased pneumonia risk a systematic review and meta analysis of randomized controlled trials combined modality treatment with chemotherapy radiotherapy and immunotherapy is a crucial therapeutic approach for lung cancer however controversies still exist regarding radiation doses treatment regimens and the risk of pneumonitis this study aimed to conduct a comprehensive meta analysis and in depth subgroup analyses based on randomized controlled trials rcts involving lung cancer patients undergoing radiotherapy to assess whether its combination with immunotherapy is effective and safe we systematically searched pubmed cochrane central embase and major conferences for randomized trials evaluating immune checkpoint inhibitors icis plus radiotherapy in lung cancer the outcomes included progression free survival pfs overall survival os and the incidence of adverse reactions particularly focusing on pneumonitis pneumonia subgroup analyses were performed based on radiotherapy modalities the timing of icis treatment tumor stage pathological type and types of icis fifteen trials were included in this analysis the addition of icis to radiotherapy or chemoradiotherapy significantly improved pfs hr ci and os hr ci in subgroup analyses stereotactic body radiotherapy sbrt hr ci and hypo fractionated radiotherapy hypo rt hr ci were associated with improved pfs consolidation icis treatment improved os hr ci while concurrent icis had no significant effect hr ci in terms of tumor stage stage i nsclc patients hr ci showed significant pfs improvement with icis both pd hr ci and pd l hr ci inhibitors were linked to improved pfs in irradiated lung cancer patients and pd l also enhanced os hr ci the addition of icis increased the risk of any grade pneumonitis pneumonia rr ci but did not elevate the risk of severe grade events rr ci notably among patients treated with sbrt no significant increase was observed in the incidence of pneumonitis of any grade pd pd l inhibitors combined with radiotherapy especially sbrt can enhance survival outcomes in lung cancer without increasing the risk of severe pneumonitis pneumonia supporting their clinically manageable safety profile https www crd york ac uk prospero home identifier crd"
}